Key facts
- ThinkCyte’s last known valuation is $106.4M (Nov 2025).
- It has raised $84.7M; the latest was Later Stage VC ($3.9M) in Nov 2025.
- Notable investors include Google for Startups, Global Brain, SMBC Venture Capital, J-Startup, Berkeley SkyDeck — 27 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for ThinkCyte
- ·The full record, as it builds
Funding rounds
No funding rounds for ThinkCyte are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ThinkCyte
Developer of an image-based cell sorting technology designed to advance single-cell analysis for research, diagnostics, and therapeutics. The company's ghost cytometry technology integrates advanced optics, machine learning, and biotechnology and brings ultra-high throughput, content-rich analysis, and sorting on a single-cell level to disciplines such as drug discovery, cell therapy, and clinical diagnostics, enabling medical researchers to identify cells based on their images and isolate target cells, including rare cells, in real-time.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2016
- Employees
- 67
- Website
- thinkcyte.com/
- Ownership
- Privately Held (backing)
ThinkCyte doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ThinkCyte shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ThinkCyte in its N-PORT filings yet. We sweep new filings monthly.